Gsk is replacing its popular flovent inhaler with authorized generics, raising cost concerns for asthma patients
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years. Flovent’s
manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an
“authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as
fluticasone. The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect
as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be
able to avoid paying a penalty. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF
THE PHARMA INDUSTRY — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe